Tvardi Therapeutics(DE:69C)
€1.10-0.07 (-5.98%)
DE:69C
Tvardi Therapeutics earnings date
€1.10
At close:-0.07 (-5.98%)
Tvardi Therapeutics (69C) Q3 2021 Earnings Report
1 Followers
DE:69C Q3 2021 EPS Results
- Actual EPS
- -EUR 0.65
- Consensus EPS
- -EUR 12.57
- Beat/Miss
- Beat by +EUR 11.92
- One Year Ago EPS
- -EUR 11.39
DE:69C Q3 2021 Revenue Results
- Actual Revenue
- EUR 18.32M
- Expected Revenue
- EUR 14.09M
- Beat/Miss
- Beat by +EUR 4.23M
- YoY Revenue Growth
- +118.78%
Earnings Announcement Details
- Quarter
- Q3 2021
- Date
- 11/08/2021
- Time
- After Close
- Conference Call
- Monday, November 8, 2021
DE:69C Upcoming Earnings
Tvardi Therapeutics's next earnings date is estimated for April 6, 2027, based on past reporting schedules.
Q3 2021 Earnings Call Audio
No earnings call audio is available for this earnings event.
Q3 2021 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2021 Earnings Call Summary
No earnings call summary is available for this earnings event.
DE:69C Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 06, 2027 | 2026 (Q4) | ―- | -0.66 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | -0.52-0.48 | -0.53 | 9.32% (+0.05) | |
| Aug 14, 2026 | 2026 (Q2) | -0.64-0.62 | -0.9 | 31.00% (+0.28) | |
| May 08, 2026 | 2026 (Q1) | ―- | -2.91 | ― | |
| Mar 31, 2026 | 2025 (Q4) | -0.67-0.66 | -2.91 | 77.33% (+2.25) | |
| Nov 13, 2025 | 2025 (Q3) | -0.90-0.53 | -7.4 | 92.80% (+6.87) | |
| Aug 14, 2025 | 2025 (Q2) | -0.62-0.90 | -11.9 | 92.41% (+11.00) | |
| May 13, 2025 | 2025 (Q1) | -0.53-2.91 | -18.22 | 84.03% (+15.31) | |
| Feb 26, 2025 | 2024 (Q4) | ―-1.52 | -6.4 | 76.27% (+4.88) | |
| Nov 04, 2024 | 2024 (Q3) | -0.22-0.21 | -0.47 | 56.15% (+0.26) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat Missed
